For Health Professionals

Clinical Research

Research Volunteers

Why Participate in Clinical Research?

You will contribute to the wellbeing of society, and the advancement of medical research, bringing new hope for patients afflicted with different conditions and diseases. Future generations, your children or grandchildren included, will benefit from the research. It may also benefit you, as you can learn more about your illness or condition and the treatment options, and have access to new medications and procedures. Whatever your reasons, participation is voluntary. We invite you to join us in gaining better understanding of diseases and improving healthcare in Singapore.

Information

Eligibility:

  • High blood pressure before 30 years old
  • High blood pressure between 30 - 40 years old and family history of hypertension
  • Uncontrolled high blood pressure despite taking 3 or more blood pressure lowering medications
  • Your doctor suspects that you may have Monogenic Hypertension

Contact Number:

 8938 2077 / 9646 6874 

Email:

[email protected]

Time:

Monday - Friday,
9am - 12pm or 1pm - 5pm

Collection, use and disclosure of your personal data shall be in accordance with our privacy policy

We are looking for volunteers for a 3-year study to find out which of two treatment processes is better at treating Type 2 Diabetes in overweight patients: Surgery or the best medical treatment.

Information

Eligibility:

  • Type 2 diabetes for less than 10 years
  • Age 21 – 65 years old
  • BMI between 27 - 32
  • Willing to have either surgery or the best medical treatment
  • Not pregnant or planning to get pregnant before the end of the study

Contact :

973 874 08

Email:

[email protected]

Collection, use and disclosure of your personal data shall be in accordance with our privacy policy

We are calling for research volunteers who have taken part in the diabetes study in 2011-2014 organised by Khoo Teck Puat Hospital's Clinical Research Unit to participate in a follow-up study. This research investigates the risk factors affecting blood vessel function, eye, kidney and foot complications in people with Type 2 diabetes.

Information

Eligibility:

  • Aged 21 to 90 years old
  • Have Type 2 Diabetes
  • Not pregnant

Contact :

8128 9442 (Amy)
8798 3468 (Xiaoge)
8798 3592 (Siti)
9113 5891 (Wei Rou)

Email:

[email protected]

Time:

Monday - Friday,
9am - 12pm or 2pm - 4.30pm

DKD is a common diabetic complication which affects the kidneys. Over time, kidney function is lost, leading to the need for dialysis. DKD patients commonly experience a loss in their quality of life.

Research has shown that DKD tends to occur more frequently within families with a history of DKD. This pattern may be caused by a shared lifestyle among family members. This includes shared diet and behavior.

Information

Eligibility:

  • T2DM 10 years
  • At least 2 family members can join
  • Family members need not to be T2DM 10 years

Contact Number:

Office - 6602 3311

HP - 9758 6282 (8am - 8pm) 

Email:

[email protected]

Collection, use and disclosure of your personal data shall be in accordance with our privacy policy

MODY (Maturity-Onset Diabetes of the Young) is a form of monogenic diabetes that is caused by a single gene abnormality (mutation). Our research study aims to identify potential MODY patients for genetic testing in order to determine the mutation which will help doctors better understand the disease and treat the patients. The MODY Registry provides a platform to gather information for further studies of monogenic diabetes that will serve the interests of patients and healthcare providers.

Information

Principal Investigator:

A/Prof Lim Su Chi

Senior Consultant, Diabetes Centre 

Clinical Director, Clinical Research Unit, Khoo Teck Puat Hospital

Recruitment Period:

Until 30 September 2021

Eligibility:

  • Age 0-99 years 
  • Diabetes diagnosed at 35 years old or less
  • Additional criteria applies (eligibility to be confirmed by study team)

Cost:

For eligible and consented participants:

  • No charge for tests performed as part of the study
  • One-time transport reimbursement provided

Contact :

9755 2352 (Li Xian)
9839 9844 (Lovynn)

Email:

[email protected]

Time:

Monday - Friday,
9am - 12pm or 2pm - 4.30pm

Collection, use and disclosure of your personal data shall be in accordance with our privacy policy

 

Information​

  Recru​itment Period:

Until 31 March 2030

 Eligibility (must fulfill all the criteria):

  • ​Total Cholesterol > 7.5 mmol/L and/or LDL cholesterol > 4.9 mmol/L
  • Family history of high cholesterol and heart diseases

 What the study involves:

  • Up to 2 visits
  • Family history taking
  • Sample collection for genetic testing

 Cost:

Cost of genetic test for Familial ​Hypercholesterolemia (FH) will be advised by the team upon request.

 Contact :

6807 8212 / 6602 2346
9863 7690 (Atiqa)
9674 5167 (Husna)
9825 9793 (Sharmaine)
9119 4957 (Madhuu)

 Email:

[email protected]

 Websi​te:

Familial Hypercholesterolemia

 Time:

Monday - Friday,
9am - 12pm or 2pm - 5pm


Collection, use and disclosure of your personal data shall be in accordance with our privacy policy

You may contact the study teams for specific studies as listed in the recruitment posters above.

Alternatively, you may click here to register your interest to be part of our research volunteers database. We will contact you when there is a suitable study.

Participant Information & Rights

Association for the Accreditation of Human Research Protection Programs

For our efforts in achieving a high standard for ethics, quality and protection of people in research, KTPH is one of the few institutions in Singapore to be awarded the Full Accreditation by the Association for the Accreditation of Human Research Protection Programs (AAHRPP).

AAHRPP is a non-profit organisation that accredits institutions conducting research for achieving high quality of research work and protection of participants.

To attain the accreditation, KTPH has to submit report on its Human Research Protection Programs and undergo stringent on-site review by a team of experts from AAHRPP at scheduled intervals. For more information, please visit AAHRPP website.

ICH E6(R2) Good Clinical Practice (ICH E6 GCP) Guidelines

At KTPH, the wellbeing and safety of research participants take precedence above all our activities. To ensure the protection of our participants in clinical trial and reliability of clinical trial results, KTPH adheres to the guideline provided by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). For more information and copy of the guidelines, please visit the ICH website.

All clinical research or clinical trials require ethics approval prior to commencement.

Frequently Asked Questions

What is clinical research?

Clinical research refers to the entire process whereby a drug is incepted in the lab and eventually introduced to the consumer market. Promising drug candidate identified in lab is subjected to pre-clinical studies and animal studies for safety and toxicity tests before permission from regulatory authorities is obtained to initiate trials on human subjects.

What is a clinical trial?

There are four phases of clinical trials, each having a different aim.

  • Phase I – Phase I studies are the first stage of testing in human subjects to test for the safety, tolerability and the general mechanism of action of the drug in humans. The drug is administered to a small number of healthy volunteers to determine the dose tolerability in human subjects. Currently, KTPH does not conduct Phase studies.
  • Phase II – Phase II studies determine the efficacy of the drug or device with volunteers with a specific disease.
  • Phase III - Phase III studies determine the safety and efficacy of the investigational drug or device in different clinical settings. The outcome of the trial would be used for the basis of labeling in the market.
  • Phase IV – Phase IV studies determine long term safety and new indications to the label after it is cleared by regulatory authorities for marketing.

Who can participate?

All clinical trials have guidelines on participants of clinical trials called the inclusion/exclusion criteria. These criteria are based on factors like age, gender,  the type and stage of a disease, previous treatment history and other medical conditions. It is important to note that inclusion and exclusion criteria are not used to reject people personally. Instead, they are used to identify appropriate participants to ensure their safety and well-being. The criteria also help to ensure that researchers will be able to answer the questions they plan to study.

What are the benefits and risks of participating in a clinical trial?

Benefits:

Well-designed and well-executed clinical trials are the best approach for eligible participants to:

  • Play an active role in their healthcare by speeding up potentially more effective new treatments
  • Contribute to research efforts that can lead to potentially better health treatment for themselves and their future generation
  • Gain access to new and potentially more effective treatment before they are widely available
  • Receive expert medical care at leading health facilities during the trial

Risks:

Clinical research, like medical treatments, always involve risks.

  • There may be unpleasant, serious or even life-threatening side effects resulting from the treatment.
  • The new treatment may not be as effective as currently available treatments.

How is the safety of participants protected?

All clinical trials are regulated by the Medicines Act 1975 and the Medicines (Clinical Trials) (Amendment) Regulations 1998. In addition, research studies conducted in KTPH must seek ethics approval from an independent ethics committee called the Domain Specific Review Boards (DSRB). The committee includes medical doctors, paramedical staff, statisticians and volunteers from the public who collectively review all research proposals. The rights, safety and wellbeing of trial participants are the most important considerations and prevail over interests of science and society.

Before a trial is initiated, a detailed research proposal is to be submitted for ethical review to the DSRB. As a clinical trial progresses, study status reports will be submitted periodically to DSRB and if necessary, random audits will be conducted to ensure protocol compliance. Individual participants’ names will not be reported to protect participants'confidentiality.

What should people consider before participating in a trial?

Before participating in a trial, potential participants should know as much as possible about the trial. He or she should feel comfortable raising questions and concerns pertaining to the trial to the study team. Below is a list of some questions that can help in understanding a trial before participating:

  • What is the purpose of the study?
  • Why do researchers believe the new treatment being studied may be effective, or more effective than standard treatment? Has it been tested before?
  • What kinds of tests and treatments are involved?
  • Were there any serious side effects in pre-clinical studies?
  • How do the possible risks, side effects and benefits in the study compare with my current treatment?
  • What minor side effects should I be aware of?
  • How might this trial affect my daily life?
  • How long will the trial last?
  • How will I know that the treatment is effective? - Will results of the trials be provided to me?
  • Will I be informed of updates in any new available treatment?
  • Will hospitalization be required?
  • Who will pay for the treatment?
  • Will I be reimbursed for expenses?
  • Can I withdraw from the trial after it has begun?
  • Will I be denied medical care if I withdraw from trial?

Who pays for clinical research?

The hospital funds promising clinical studies initiated by doctors as part of our ongoing commitment to promote, develop and provide health-related services that will benefit the Singapore community. Additional funding may come from government organisations, such as National Research Foundation (NRF), National Medical Research Council (NMRC) or private industry (via pharmaceutical and biotech companies).